This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ResMed's Management Hosts Deutsche Bank AG Health Care Conference Call (Transcript)

ResMed Inc. (RMD)

Deutsche Bank AG Health Care Conference Call

May 8, 2012 10:00 am EDT


David Pendarvis – Chief Administrative Officer and Global General Counsel


David Low – Deutsche Bank


David Low – Deutsche Bank

Good morning, everyone. My name is David Low. I cover Healthcare stocks out of Australia, including ResMed, which has obviously got dual listing. Today, we've got David Pendarvis, who is the Chief Administrative Officer at ResMed. David's got ten years' experience at ResMed. And he's going to give us a presentation and then take a few questions. Thanks very much, David.

David Pendarvis

Fantastic. Thank you, David, and thanks to Deutsche Bank for having us, and for covering the ResMed both here, obviously, and down on the Australian Stock Exchange, where we are dual listed. So, the forward-looking statements, obviously, hold on to your seat belts when we predict things, we can at sometimes be wrong. And I want to really focus on sort of three main points here.

If you take nothing else away from this presentation, it's that ResMed really is sort of the Holy Grail of healthcare, in the sense that we do three things, we prevent disease, in particular the disease of sleep apnea and we improve the quality of life.

But, we also reduced the cost of health care. So, as systems around the world are trying to struggle with delivering higher quality for less cost. We do that and we do that in this space. So, those are really the three primary things that ResMed delivers here.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSLA $232.74 -3.70%
YHOO $35.82 -1.90%
AAPL $95.37 1.80%
FB $117.24 -1.10%
GOOG $690.20 -1.10%


Chart of I:DJI
DOW 17,628.94 -121.97 -0.69%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs